By Budi Oetomo Narendra 
CHICAGO, IL – A groundbreaking experimental cancer treatment, developed by researchers at the University of Illinois Chicago (UIC), leverages the unique properties of bacteria residing within tumors to disrupt cancer cells’ energy production. The innovative approach, detailed in findings published in the esteemed journal Signal Transduction and Targeted Therapy, has demonstrated striking efficacy in preclinical studies involving prostate cancer, particularly when combined with radiation therapy, by effectively halting tumor growth through a targeted attack on the cancer cells’ vital energy supply.
At the heart of this novel therapy is a small fragment of a bacterial protein, named aurB, derived from auracyanin. This peptide has shown the remarkable ability to infiltrate tumor cell mitochondria – often referred to as the "energy factories" of cells – and interfere with their ability to generate ATP, the primary molecular fuel required for cellular growth and survival. The significance of this discovery lies in its potential to offer a new therapeutic avenue, especially for cancers that have developed resistance to existing treatments or those with common genetic mutations that limit the effectiveness of other targeted therapies.
Targeting Cancer’s Insatiable Energy Demands
Cancer cells are notoriously aggressive and rapidly proliferating, a characteristic that necessitates an exceptionally high energy demand. This metabolic reprogramming often leads to an increase in both the number and activity of mitochondria within malignant cells, making these organelles an "ideal target for cancer therapy," according to Tohru Yamada, senior author of the study and an associate professor in the departments of surgery and biomedical engineering at UIC, as well as a member of the University of Illinois Cancer Center.
Mitochondria are complex organelles responsible for cellular respiration, the process by which cells convert nutrients into ATP. In many cancers, this process is hijacked and accelerated, allowing tumor cells to fuel their relentless division and expansion. By targeting ATP synthase, a crucial enzyme in the mitochondrial energy production pathway, aurB effectively starves the tumor cells of the fuel they need to grow, leading to their eventual demise or dormancy. This metabolic vulnerability represents a critical Achilles’ heel for many cancers, and therapies that exploit this weakness are gaining increasing attention in oncology research.
The Evolving Understanding of the Tumor Microenvironment
For decades, the tumor microenvironment (TME) has been recognized as a complex ecosystem comprising cancer cells, immune cells, stromal cells, blood vessels, and various signaling molecules. More recently, scientific inquiry has expanded to include the role of microbial communities, specifically bacteria, residing within tumors. It is now understood that these intratumoral bacteria are not merely opportunistic invaders but integral components of the TME, influencing tumor progression, metastasis, and response to therapy.
The pioneering work of Yamada’s laboratory and others has shifted the paradigm from viewing bacteria solely as pathogens to recognizing their untapped potential as sources of novel therapeutic agents. This field, often termed "bio-prospecting" within the tumor microbiome, seeks to identify naturally occurring compounds produced by these bacteria that possess anti-cancer properties. The current discovery of aurB is a testament to this evolving understanding, demonstrating that the very environment fostering cancer growth can also harbor its potential undoing.
A Chronology of Discovery: From Cupredoxins to p53-Independent Therapies
The journey to aurB is a story of persistent scientific inquiry and adaptation, building upon previous discoveries from Yamada’s lab. Earlier research by the team had identified a different bacterial protein, a cupredoxin, capable of suppressing tumor growth. Cupredoxins are a class of copper-containing proteins known for their role in electron transfer between other proteins, a fundamental process in many biological systems.
Based on this initial discovery, Yamada’s team successfully developed a peptide drug derived from this cupredoxin, which underwent extensive testing, including promising results in clinical trials for adults and studies on pediatric brain cancer. However, a significant limitation of this earlier peptide was its reliance on the function of the p53 gene. The p53 gene, often dubbed the "guardian of the genome," plays a critical role in preventing cancer by regulating cell division and inducing apoptosis (programmed cell death) when DNA damage occurs. Unfortunately, p53 is frequently mutated in a wide array of human cancers – estimated to be altered in over 50% of all human cancers – and these mutations are highly varied, leading to a spectrum of functional deficiencies. This variability meant that the p53-dependent therapy might be highly effective for some patients but ineffective for others whose p53 gene was mutated or non-functional.
Recognizing this challenge, the research team set a new objective: to identify an anti-cancer agent that could operate independently of p53 function. "We wanted to have an anti-cancer agent that doesn’t use the p53 function," Yamada articulated, underscoring the critical need for broader applicability in cancer treatment. This strategic shift led them to explore alternative bacterial proteins that could directly target the mitochondria, bypassing the p53 pathway altogether.
The breakthrough came when researchers meticulously analyzed tumor samples from breast cancer patients using advanced DNA sequencing techniques to map the bacterial species present. One particular bacterial species caught their attention because it harbored a cupredoxin protein known as auracyanin. Auracyanin performs a function similar to the previously studied cupredoxin but presented a new opportunity to develop a p53-independent mechanism of action. From auracyanin, the team ingeniously designed and synthesized a novel peptide, which they named aurB. Subsequent laboratory experiments confirmed that aurB possessed the desired characteristics: it could efficiently enter tumor cell mitochondria and specifically bind to ATP synthase, thereby disrupting the very engine of cancer cell energy production.
Striking Preclinical Results in Aggressive Prostate Cancer Models
The efficacy of aurB was rigorously evaluated in preclinical models, specifically focusing on cancer cell lines lacking active p53 – a direct test of its p53-independent mechanism – and in sophisticated mouse models of hormone therapy-resistant prostate cancer. Prostate cancer is the second most common cancer in men globally, with hundreds of thousands of new diagnoses annually. While treatments like radiation therapy and hormone therapy are often effective in early stages, a significant challenge arises when the disease becomes resistant to hormone therapy, leading to more aggressive and difficult-to-treat forms of the disease.
The results were compelling. When aurB was administered in combination with radiation therapy – a cornerstone treatment for prostate cancer – it produced a substantial reduction in tumor growth. Critically, these therapeutic benefits were observed without signs of significant systemic toxicity, a crucial factor for any potential clinical application. "The combination significantly enhanced the activity of the peptide, and the tumor became much smaller," Yamada reported. "This approach is promising. Using a well-established tibial bone metastatic model, we demonstrated significant inhibition of tumor growth, preclinically." The success in a model of metastatic prostate cancer, particularly one resistant to standard hormone therapy, highlights aurB’s potential to address some of the most challenging aspects of cancer treatment.
Broader Implications and the Road Ahead for Bacterial-Derived Therapies
The successful development and preclinical validation of aurB represent more than just a new potential treatment for prostate cancer; it signifies a broader paradigm shift in cancer drug discovery. The ability to identify and harness specific bacterial proteins from within the tumor microenvironment to target cancer’s metabolic vulnerabilities opens up a vast, largely unexplored frontier for novel therapeutics.
UIC’s Office of Technology Management has already recognized the immense potential of aurB, securing patent protection for the novel compound. The research team is now actively exploring pathways to advance this promising therapy into human clinical trials, a critical next step that involves rigorous testing in humans to assess safety, dosage, and efficacy. This translational phase typically progresses through multiple stages (Phase I, II, and III trials) and requires significant investment and collaboration.
Beyond aurB, Yamada holds an optimistic vision for the future of bacterial-derived cancer drugs. He firmly believes that auracyanin is merely the tip of the iceberg, with countless other bacterial proteins remaining unexplored, each potentially holding the key to new cancer therapies. "There are many other bacterial proteins that could be source of cancer drugs," Yamada asserted. "We simply haven’t tried them yet." This perspective suggests a future where the tumor microbiome could become a rich bio-pharmaceutical reservoir, yielding a diverse arsenal of targeted agents against various cancers.
The implications extend beyond just new drugs. This research reinforces the growing understanding of the intricate interplay between microbes and human health, particularly in the context of disease. It paves the way for a deeper exploration of the tumor microbiome, not only for therapeutic compounds but also for diagnostic markers and predictors of treatment response.
The project’s success is a testament to collaborative science, with Yamada acknowledging critical contributions from colleagues across UIC’s College of Medicine and UI Health. Specifically, he credited the Department of Surgery, including Drs. Martin Borhani, Aslam Ejaz, Ajay Rana, Enrico Benedetti, and Tapas K. Das Gupta, for their instrumental roles. Additional UIC authors on the study include Dr. Samer A. Naffouje, Duy Binh Tran, Konstantin Christov, Albert Green, Ngoc Hai Trieu Phong, and Dr. Tapas K. Das Gupta from the College of Medicine, along with Weiguo Li from the College of Engineering. This interdisciplinary approach, combining expertise in surgery, biomedical engineering, and molecular biology, was vital in bringing this complex scientific endeavor to fruition.
As the scientific community continues to unravel the mysteries of cancer and its microenvironment, discoveries like aurB offer renewed hope for more effective, less toxic, and broadly applicable cancer treatments, moving closer to a future where cancer can be managed with greater precision and success. The journey from a bacterial fragment to a potentially life-saving drug underscores the enduring power of curiosity-driven research and its profound impact on human health.
